Janus Henderson Group PLC boosted its stake in Odonate Therapeutics Inc (NASDAQ:ODT) by 8.0% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 1,160,742 shares of the company’s stock after acquiring an additional 86,394 shares during the period. Janus Henderson Group PLC’s holdings in Odonate Therapeutics were worth $22,530,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Birchview Capital LP acquired a new position in shares of Odonate Therapeutics during the third quarter worth about $388,000. Schwab Charles Investment Management Inc. grew its position in shares of Odonate Therapeutics by 19.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 34,137 shares of the company’s stock worth $754,000 after buying an additional 5,601 shares in the last quarter. Alps Advisors Inc. acquired a new position in shares of Odonate Therapeutics during the second quarter worth about $862,000. Northern Trust Corp grew its position in shares of Odonate Therapeutics by 6.0% during the second quarter. Northern Trust Corp now owns 74,510 shares of the company’s stock worth $1,645,000 after buying an additional 4,204 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Odonate Therapeutics by 375.7% during the second quarter. Bank of New York Mellon Corp now owns 81,426 shares of the company’s stock worth $1,799,000 after buying an additional 64,310 shares in the last quarter. Hedge funds and other institutional investors own 92.23% of the company’s stock.

In other news, CEO Kevin C. Tang acquired 10,000 shares of Odonate Therapeutics stock in a transaction on Thursday, November 1st. The stock was bought at an average price of $14.87 per share, for a total transaction of $148,700.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Boxer Capital, Llc acquired 26,824 shares of Odonate Therapeutics stock in a transaction on Wednesday, October 24th. The stock was purchased at an average price of $14.72 per share, with a total value of $394,849.28. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 273,761 shares of company stock valued at $4,882,129. 49.00% of the stock is owned by company insiders.

Shares of ODT opened at $14.56 on Friday. Odonate Therapeutics Inc has a 52-week low of $14.06 and a 52-week high of $32.00.

Odonate Therapeutics (NASDAQ:ODT) last issued its quarterly earnings data on Tuesday, October 23rd. The company reported ($0.98) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.96) by ($0.02). On average, sell-side analysts predict that Odonate Therapeutics Inc will post -3.49 EPS for the current fiscal year.

Separately, Zacks Investment Research raised Odonate Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 18th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $31.00.

TRADEMARK VIOLATION NOTICE: This article was originally published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/odonate-therapeutics-inc-odt-shares-bought-by-janus-henderson-group-plc/2667103.html.

Odonate Therapeutics Profile

Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc also conducting a Phase III study in MBC, which is known as CONTESSA.

Featured Article: Fundamental Analysis – How It Helps Investors

Want to see what other hedge funds are holding ODT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Odonate Therapeutics Inc (NASDAQ:ODT).

Institutional Ownership by Quarter for Odonate Therapeutics (NASDAQ:ODT)

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.